Posted 11 months ago (0 comments)
The Johns Hopkins Wilmer Eye Institute is currently recruiting patients for a new clinical study using celecoxib (Celebrex), a non-steroidal anti-inflammatory drug approved by the Food and Drug Administration (FDA) for the treatment of pain, osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as a treatment for active thyroid eye disease (TED). The study is intended to evaluate the efficacy of COX-2 inhibition in the treatment of active TED and its ability to improve both the acute inflammatory signs and more permanent fibrotic changes of quiescent disease. Participants must be between the ages of 18 and 80, have a new diagnosis of TED (within the last six months), and have eye signs and symptoms of TED. Participants will be treated for 3 months (a characteristic period of disease activity) and the results will be compared to standard treatments for mild TED (observation and over-the-counter interventions, such as lubricant eye drops) to assess efficacy. For more information about enrolling in the study, please call the Wilmer Eye Institute at 443.287.5316 and ask to speak to Shelley Casey.